506 related articles for article (PubMed ID: 31164885)
1. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
Geller A; Yan J
Front Immunol; 2019; 10():1074. PubMed ID: 31164885
[TBL] [Abstract][Full Text] [Related]
2. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
[TBL] [Abstract][Full Text] [Related]
3. Immune evasion of tumor cells using membrane-bound complement regulatory proteins.
Gorter A; Meri S
Immunol Today; 1999 Dec; 20(12):576-82. PubMed ID: 10562709
[TBL] [Abstract][Full Text] [Related]
4. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
[TBL] [Abstract][Full Text] [Related]
5. The role of membrane complement regulatory proteins in cancer immunotherapy.
Yan J; Allendorf DJ; Li B; Yan R; Hansen R; Donev R
Adv Exp Med Biol; 2008; 632():159-74. PubMed ID: 19025121
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
8. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
9. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model.
Gelderman KA; Hakulinen J; Hagenaars M; Kuppen PJ; Meri S; Gorter A
Mol Immunol; 2003 Sep; 40(1):13-23. PubMed ID: 12909127
[TBL] [Abstract][Full Text] [Related]
10. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
[TBL] [Abstract][Full Text] [Related]
11. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
Gelderman KA; Blok VT; Fleuren GJ; Gorter A
Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of membrane-bound complement regulatory proteins suppresses colon cancer growth in mice through inducing tumor cell apoptosis.
Tang G; Pan L; Wang Z; Zhu H; Yang Y; Wang Z; Yue H; Shi Y; Wu D; Jiang Z; Jiang D
Int Immunopharmacol; 2023 Jan; 114():109450. PubMed ID: 36446233
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the expression of complement inhibitory proteins and therapeutic efficacy of antibodies in breast cancer.
Montalvo-Castro RE; Salinas-Jazmín N
Gac Med Mex; 2022; 158(3):141-149. PubMed ID: 35894744
[TBL] [Abstract][Full Text] [Related]
16. Analysis of membrane-bound complement regulatory proteins in prostate cancer.
Loberg RD; Wojno KJ; Day LL; Pienta KJ
Urology; 2005 Dec; 66(6):1321-6. PubMed ID: 16360477
[TBL] [Abstract][Full Text] [Related]
17. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury.
Song WC
Curr Dir Autoimmun; 2004; 7():181-99. PubMed ID: 14719381
[TBL] [Abstract][Full Text] [Related]
18. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
[TBL] [Abstract][Full Text] [Related]
19. HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-κB signaling to protect breast cancer cells from complement attack.
Cui W; Zhao Y; Shan C; Kong G; Hu N; Zhang Y; Zhang S; Zhang W; Zhang Y; Zhang X; Ye L
FEBS Lett; 2012 Mar; 586(6):766-71. PubMed ID: 22293503
[TBL] [Abstract][Full Text] [Related]
20. Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE.
Das N; Biswas B; Khera R
Adv Exp Med Biol; 2013; 735():55-81. PubMed ID: 23402019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
